Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30447863 | 1.00 | NPSR1 (0.45) | NPSR1POLBSYKL3MBTL1ALDH1A1 | |
| SCHEMBL30447606 | 0.86 | NPSR1 (0.44) | NPSR1POLBSYKL3MBTL1ALDH1A1 | |
| SCHEMBL30447697 | 0.86 | NPSR1 (0.44) | NPSR1POLBSYKL3MBTL1ALDH1A1 | |
| SCHEMBL30878162 | 0.83 | POLB (0.47) | NPSR1POLBSYKL3MBTL1ALDH1A1 | |
| SCHEMBL30307663 | 0.83 | POLB (0.47) | NPSR1POLBSYKL3MBTL1ALDH1A1 | |
| SCHEMBL2499502 | 0.83 | POLB (0.47) | NPSR1POLBSYKL3MBTL1ALDH1A1 | |
| SCHEMBL19456479 | 0.83 | POLB (0.47) | NPSR1POLBSYKL3MBTL1ALDH1A1 | |
| SCHEMBL4679985 | 0.81 | SYK (0.47) | POLBSYKL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23491355 | 0.78 | SYK (0.45) | NPSR1POLBSYKL3MBTL1ALDH1A1 | |
| SCHEMBL23491247 | 0.78 | SYK (0.45) | NPSR1POLBSYKL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4444728-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | Pretzel Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107487-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | LONP1, NLN, ACAT1 | NPSR1 4379/4885POLB 320/4885SYK 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.